Colin Stott

Phytanix Bio, a preclinical stage pharmaceutical company, has released an updated investor deck. The presentation showcases a business strategy aimed at developing new cannabinoid-based pharmaceuticals. The company, which has ties to historical pharmaceutical developments in the cannabis industry,...

Chain Bridge I (NASDAQ:CBRG) announced on Monday the acquisition of Phytanix Bio, a pharmaceutical company specializing in the development of therapeutics based on cannabinoid and cannabinoid-like molecules. The transaction, valued at $58 million, also includes the assumption of preferred stock and...